(Q37344236)

19 August 2017

1 reference

title

HIV/AIDS vaccines: a need for new concepts? (English)

1 reference

19 August 2017

0 references

Marc P Girard

1

1 reference

19 August 2017

Geetha P Bansal

series ordinal

2

1 reference

19 August 2017

publication date

1 January 2008

1 reference

International Reviews of Immunology

19 August 2017

published in

1 reference

19 August 2017

volume

27

1 reference

19 August 2017

issue

6

1 reference

19 August 2017

page(s)

447-471

1 reference

The failed HIV Merck vaccine study: a step back or a launching point for future vaccine development?

19 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1080%2F08830180802432160

Human versus HIV: round 2 defeat in AIDS vaccine development

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180802432160

Public health. AIDS vaccine trial produces disappointment and confusion

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180802432160

Correlation between immunologic responses to a recombinant glycoprotein 120 vaccine and incidence of HIV-1 infection in a phase 3 HIV-1 preventive vaccine trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180802432160

Prevention of HIV-1 infection in chimpanzees by gpl20 V3 domain-specific monoclonal antibody

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180802432160

Antibody protects macaques against vaginal challenge with a pathogenic R5 simian/human immunodeficiency virus at serum levels giving complete neutralization in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180802432160

Passive immunization with human neutralizing monoclonal antibodies: correlates of protective immunity against HIV.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180802432160

Conserved sequence and structural elements in the HIV-1 principal neutralizing determinant

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180802432160

Protection of chimpanzees from infection by HIV-1 after vaccination with recombinant glycoprotein gp120 but not gp160.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180802432160

HIV-1 envelope-elicited neutralizing antibody titres correlate with protection and virus load in chimpanzees

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180802432160

GP120: target for neutralizing HIV-1 antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180802432160

Neutralization of human immunodeficiency virus type 1 by sCD4-17b, a single-chain chimeric protein, based on sequential interaction of gp120 with CD4 and coreceptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180802432160

HIV-1 evades antibody-mediated neutralization through conformational masking of receptor-binding sites

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180802432160

Antibody neutralization and escape by HIV-1

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180802432160

Immunization with envelope subunit vaccine products elicits neutralizing antibodies against laboratory-adapted but not primary isolates of human immunodeficiency virus type 1. The National Institute of Allergy and Infectious Diseases AIDS Vaccine Ev

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180802432160

Rapid evolution of the neutralizing antibody response to HIV type 1 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180802432160

HIV vaccine design and the neutralizing antibody problem

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180802432160

Inhibition of HIV-1 entry by antibodies: potential viral and cellular targets

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180802432160

Structure-based, targeted deglycosylation of HIV-1 gp120 and effects on neutralization sensitivity and antibody recognition.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180802432160

Removal of a single N-linked glycan in human immunodeficiency virus type 1 gp120 results in an enhanced ability to induce neutralizing antibody responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180802432160

Protection of macaques against vaginal SHIV challenge by systemic or mucosal and systemic vaccinations with HIV-envelope

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180802432160

Characterization of human immunodeficiency virus type 1 monomeric and trimeric gp120 glycoproteins stabilized in the CD4-bound state: antigenicity, biophysics, and immunogenicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180802432160

Crosslinked HIV-1 envelope-CD4 receptor complexes elicit broadly cross-reactive neutralizing antibodies in rhesus macaques

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180802432160

Polyvalent HIV-1 Env vaccine formulations delivered by the DNA priming plus protein boosting approach are effective in generating neutralizing antibodies against primary human immunodeficiency virus type 1 isolates from subtypes A, B, C, D and E.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180802432160

Cross-subtype antibody and cellular immune responses induced by a polyvalent DNA prime-protein boost HIV-1 vaccine in healthy human volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180802432160

Cytotoxic-T-cell responses, viral load, and disease progression in early human immunodeficiency virus type 1 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180802432160

Human immunodeficiency virus type 1-specific cytotoxic T lymphocyte activity is inversely correlated with HIV type 1 viral load in HIV type 1-infected long-term survivors

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180802432160

Multifunctional human immunodeficiency virus (HIV) gag-specific CD8+ T-cell responses in rectal mucosa and peripheral blood mononuclear cells during chronic HIV type 1 infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180802432160

HIV controllers exhibit potent CD8 T cell capacity to suppress HIV infection ex vivo and peculiar cytotoxic T lymphocyte activation phenotype

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180802432160

HIV nonprogressors preferentially maintain highly functional HIV-specific CD8+ T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180802432160

Superior control of HIV-1 replication by CD8+ T cells is reflected by their avidity, polyfunctionality, and clonal turnover

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180802432160

Control of viremia in simian immunodeficiency virus infection by CD8+ lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180802432160

T cell vaccines for microbial infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180802432160

DNA vaccines against human immunodeficiency virus type 1 in the past decade

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180802432160

Multiple effects of codon usage optimization on expression and immunogenicity of DNA candidate vaccines encoding the human immunodeficiency virus type 1 Gag protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180802432160

A dose sparing effect by plasmid encoded IL-12 adjuvant on a SIVgag-plasmid DNA vaccine in rhesus macaques

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180802432160

Protection against simian/human immunodeficiency virus (SHIV) 89.6P in macaques after coimmunization with SHIV antigen and IL-15 plasmid

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180802432160

Effect of plasmid DNA vaccine design and in vivo electroporation on the resulting vaccine-specific immune responses in rhesus macaques

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180802432160

Human immunodeficiency virus type 1 vaccine development: recent advances in the cytotoxic T-lymphocyte platform "spotty business".

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180802432160

The prime-boost strategy: exciting prospects for improved vaccination

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180802432160

Viral vectors as potential HIV-1 vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180802432160

Hexon-chimaeric adenovirus serotype 5 vectors circumvent pre-existing anti-vector immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180802432160

Replication-deficient human adenovirus type 35 vectors for gene transfer and vaccination: efficient human cell infection and bypass of preexisting adenovirus immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180802432160

Comparative seroprevalence and immunogenicity of six rare serotype recombinant adenovirus vaccine vectors from subgroups B and D

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180802432160

A simian replication-defective adenoviral recombinant vaccine to HIV-1 gag.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180802432160

Effect of preexisting immunity to adenovirus human serotype 5 antigens on the immune responses of nonhuman primates to vaccine regimens based on human- or chimpanzee-derived adenovirus vectors

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180802432160

A CD46-binding chimpanzee adenovirus vector as a vaccine carrier.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180802432160

Enhanced SIV replication and accelerated progression to AIDS in macaques primed to mount a CD4 T cell response to the SIV envelope protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180802432160

Enhanced sensitivity of detection of cytotoxic T lymphocyte responses to HIV type 1 proteins using an extended in vitro stimulation period for measuring effector function in volunteers enrolled in an ALVAC-HIV phase I/II prime boost vaccine trial in

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180802432160

Control of a mucosal challenge and prevention of AIDS by a multiprotein DNA/MVA vaccine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180802432160

DNA/MVA vaccine for HIV type 1: effects of codon-optimization and the expression of aggregates or virus-like particles on the immunogenicity of the DNA prime

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180802432160

An HIV-1 clade C DNA prime, NYVAC boost vaccine regimen induces reliable, polyfunctional, and long-lasting T cell responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180802432160

Dendritic cells are preferentially targeted among hematolymphocytes by Modified Vaccinia Virus Ankara and play a key role in the induction of virus-specific T cell responses in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180802432160

Alphavirus vectors and vaccination

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180802432160

Characterization of immune responses elicited in macaques immunized sequentially with chimeric VEE/SIN alphavirus replicon particles expressing SIVGag and/or HIVEnv and with recombinant HIVgp140Env protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180802432160

Multispecific vaccine-induced mucosal cytotoxic T lymphocytes reduce acute-phase viral replication but fail in long-term control of simian immunodeficiency virus SIVmac239.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180802432160

Attenuation of simian immunodeficiency virus SIVmac239 infection by prophylactic immunization with dna and recombinant adenoviral vaccine vectors expressing Gag

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180802432160

Vaccine protection by live, attenuated simian immunodeficiency virus in the absence of high-titer antibody responses and high-frequency cellular immune responses measurable in the periphery

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180802432160

Cross-clade detection of HIV-1-specific cytotoxic T lymphocytes does not reflect cross-clade antiviral activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180802432160

Not all cytokine-producing CD8+ T cells suppress simian immunodeficiency virus replication

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180802432160

Recognition of escape variants in ELISPOT does not always predict CD8+ T-cell recognition of simian immunodeficiency virus-infected cells expressing the same variant sequences

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180802432160

Impact of vaccine-induced mucosal high-avidity CD8+ CTLs in delay of AIDS viral dissemination from mucosa

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180802432160

A novel functional CTL avidity/activity compartmentalization to the site of mucosal immunization contributes to protection of macaques against simian/human immunodeficiency viral depletion of mucosal CD4+ T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180802432160

Virological outcome after structured interruption of antiretroviral therapy for human immunodeficiency virus infection is associated with the functional profile of virus-specific CD8+ T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180802432160

Preserved CD4+ central memory T cells and survival in vaccinated SIV-challenged monkeys

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180802432160

Antiviral therapy during primary simian immunodeficiency virus infection fails to prevent acute loss of CD4+ T cells in gut mucosa but enhances their rapid restoration through central memory T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180802432160

21 January 2018

HIV/AIDS vaccines: 2007.

1 reference

https://api.crossref.org/works/10.1080%2F08830180802432160

Translating innate immunity into immunological memory: implications for vaccine development

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180802432160

A clinically relevant HIV-1 subunit vaccine protects rhesus macaques from in vivo passaged simian-human immunodeficiency virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180802432160

Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180802432160

Cytotoxic T-lymphocyte escape does not always explain the transient control of simian immunodeficiency virus SIVmac239 viremia in adenovirus-boosted and DNA-primed Mamu-A*01-positive rhesus macaques

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180802432160

Systemic vaccination prevents the total destruction of mucosal CD4 T cells during acute SIV challenge

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180802432160

HIV vaccine design: insights from live attenuated SIV vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180802432160

Nonhuman primate models and the failure of the Merck HIV-1 vaccine in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180802432160

Vaccine-induced cellular immune responses reduce plasma viral concentrations after repeated low-dose challenge with pathogenic simian immunodeficiency virus SIVmac239

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180802432160

Improved vaccine protection from simian AIDS by the addition of nonstructural simian immunodeficiency virus genes

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180802432160

Cytotoxic T lymphocyte-based control of simian immunodeficiency virus replication in a preclinical AIDS vaccine trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180802432160

Involvement of multiple epitope-specific cytotoxic T-lymphocyte responses in vaccine-based control of simian immunodeficiency virus replication in rhesus macaques

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180802432160

Long-term control of simian immunodeficiency virus replication with central memory CD4+ T-cell preservation after nonsterile protection by a cytotoxic T-lymphocyte-based vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180802432160

Protection against mucosal simian immunodeficiency virus SIV(mac251) challenge by using replicating adenovirus-SIV multigene vaccine priming and subunit boosting

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180802432160

Immunogenicity, safety, and protective efficacy of an inactivated SARS-associated coronavirus vaccine in rhesus monkeys

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180802432160

Replicating and non-replicating viral vectors for vaccine development

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180802432160

Gastrointestinal tract as a major site of CD4+ T cell depletion and viral replication in SIV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180802432160

CD4+ T cell depletion during all stages of HIV disease occurs predominantly in the gastrointestinal tract

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180802432160

Primary HIV-1 infection is associated with preferential depletion of CD4+ T lymphocytes from effector sites in the gastrointestinal tract

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180802432160

HIV disease: fallout from a mucosal catastrophe?

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180802432160

Entry of viruses through the epithelial barrier: pathogenic trickery

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180802432160

Improving defences at the portal of HIV entry: mucosal and innate immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180802432160

Transmission, acute HIV-1 infection and the quest for strategies to prevent infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180802432160

Perils at mucosal front lines for HIV and SIV and their hosts

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180802432160

Simian immunodeficiency virus-induced intestinal cell apoptosis is the underlying mechanism of the regenerative enteropathy of early infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180802432160

Early impairment of gut function and gut flora supporting a role for alteration of gastrointestinal mucosa in human immunodeficiency virus pathogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180802432160

Chronic innate immune activation as a cause of HIV-1 immunopathogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180802432160

Understanding the benign nature of SIV infection in natural hosts

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180802432160

Simian immunodeficiency virus-induced mucosal interleukin-17 deficiency promotes Salmonella dissemination from the gut.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180802432160

Cervicovaginal secretory antibodies to human immunodeficiency virus type 1 (HIV-1) that block viral transcytosis through tight epithelial barriers in highly exposed HIV-1-seronegative African women.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180802432160

Predictive value of anti-cell and anti-human immunodeficiency virus (HIV) humoral responses in HIV-1-exposed seronegative cohorts of European and Asian origin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180802432160

Secretory IgA specific for a conserved epitope on gp41 envelope glycoprotein inhibits epithelial transcytosis of HIV-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180802432160

Humoral immune responses by prime-boost heterologous route immunizations with CTB-MPR(649-684), a mucosal subunit HIV/AIDS vaccine candidate.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180802432160

A mucosally targeted subunit vaccine candidate eliciting HIV-1 transcytosis-blocking Abs.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180802432160

The membrane-proximal external region of the human immunodeficiency virus type 1 envelope: dominant site of antibody neutralization and target for vaccine design

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180802432160

Mucosal and systemic anti-HIV responses in rhesus macaques following combinations of intranasal and parenteral immunizations

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180802432160

Intranasal delivery of vaccines against HIV.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180802432160

Induction of HIV immunity in the genital tract after intranasal delivery of a MVA vector: enhanced immunogenicity after DNA prime-modified vaccinia virus Ankara boost immunization schedule

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180802432160

Intranasal HIV-1-gp160-DNA/gp41 peptide prime-boost immunization regimen in mice results in long-term HIV-1 neutralizing humoral mucosal and systemic immunity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180802432160

Clarification of how HIV-1 DNA and protein immunizations may be better used to obtain HIV-1-specific mucosal and systemic immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180802432160

DNA-VLP prime-boost intra-nasal immunization induces cellular and humoral anti-HIV-1 systemic and mucosal immunity with cross-clade neutralizing activity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180802432160

Nasal and vaginal vaccinations have differential effects on antibody responses in vaginal and cervical secretions in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180802432160

Atraumatic oral spray immunization with replication-deficient viral vector vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180802432160

CD8+ T cell efficacy in vaccination and disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180802432160

In vivo attenuation of simian immunodeficiency virus by disruption of a tyrosine-dependent sorting signal in the envelope glycoprotein cytoplasmic tail

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180802432160

Construction of a doxycycline-dependent simian immunodeficiency virus reveals a nontranscriptional function of tat in viral replication.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180802432160

Quantitation of HIV-1-Specific Cytotoxic T Lymphocytes and Plasma Load of Viral RNA

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180802432160

Mucosal and plasma IgA from HIV-exposed seronegative individuals neutralize a primary HIV-1 isolate

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180802432160

10.1080/08830180802432160

21 January 2018

Identifiers

DOI

1 reference

19 August 2017

1 reference